Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.
Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, Fahrner C, Schmitt D, Gantzer M, Remy-Ziller C, Brandely R, Villeval D, Rittner K, Silvestre N, Erbs P, Zitvogel L, Quéméneur E, Préville X, Marchand JB. Kleinpeter P, et al. Among authors: preville x. Oncoimmunology. 2016 Sep 9;5(10):e1220467. doi: 10.1080/2162402X.2016.1220467. eCollection 2016. Oncoimmunology. 2016. PMID: 27853644 Free PMC article.
Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.
Fend L, Remy-Ziller C, Foloppe J, Kempf J, Cochin S, Barraud L, Accart N, Erbs P, Fournel S, Préville X. Fend L, et al. Among authors: preville x. Oncoimmunology. 2015 Oct 6;5(2):e1080414. doi: 10.1080/2162402X.2015.1080414. eCollection 2016 Feb. Oncoimmunology. 2015. PMID: 27057460 Free PMC article.
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C, Thioudellet C, Hortelano J, Gantzer M, Nourtier V, Claudepierre MC, Sansas B, Préville X, Bendjama K, Quemeneur E, Rittner K. Remy-Ziller C, et al. Among authors: preville x. Hum Vaccin Immunother. 2018 Jan 2;14(1):140-145. doi: 10.1080/21645515.2017.1373921. Epub 2017 Oct 18. Hum Vaccin Immunother. 2018. PMID: 28925793 Free PMC article.
Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.
Claudepierre MC, Hortelano J, Schaedler E, Kleinpeter P, Geist M, Remy-Ziller C, Brandely R, Tosch C, Laruelle L, Jawhari A, Menguy T, Marchand JB, Romby P, Schultz P, Hartmann G, Rooke R, Bonnefoy JY, Preville X, Rittner K. Claudepierre MC, et al. Among authors: preville x. J Virol. 2014 May;88(10):5242-55. doi: 10.1128/JVI.03819-13. Epub 2014 Feb 26. J Virol. 2014. PMID: 24574403 Free PMC article.
Trial Watch-Oncolytic viruses and cancer therapy.
Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Pol J, et al. Among authors: preville x. Oncoimmunology. 2015 Dec 8;5(2):e1117740. doi: 10.1080/2162402X.2015.1117740. eCollection 2016 Feb. Oncoimmunology. 2015. PMID: 27057469 Free PMC article. Review.
39 results